Arvinas, Inc. (ARVN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

welcome each and every one of you to the Arvina's first quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. It is now my pleasure to turn today's call over to Arvina's Vice President of Investor Relations, Jeff Boyle. Please go ahead. Thank you, and good morning, everyone. Thanks for joining us. Earlier today, we issued a press release with our first quarter 2025 financial results, which is available in the investor and media section of our website at Arvinas.com. Joining the call today are John Houston, Arvinas' chief executive officer, president, and chairperson, Noah Berkowitz, our chief medical officer, and Andrew Saag, our chief financial officer. Our chief scientific officer, Andrew Saag, was scheduled to join us this morning, but had an unanticipated personal event and will not be able to. Before we begin the call, I'll remind you that today's discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which I urge you to read. Our actual results may differ materially from what is discussed on today's call. And now I'll turn the call over to John. Thanks, Jeff. Good morning, everyone, and thank you for joining us today. As you saw in our earnings release this morning, we have reached an important moment in Arvinas' progress as a company. We recently shared the first-ever positive pivotal data for a prototype degrader, VipDegastrant, whic...